Literature DB >> 16442083

Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology.

Paul J Harrison1, Amanda J Law.   

Abstract

Neuregulin 1 (NRG1) is a leading schizophrenia susceptibility gene. The NRG1 locus on chromosome 8p shows linkage to the disorder, and genetic association has been found between schizophrenia and various non-coding polymorphisms and haplotypes, especially at the 5' end of the NRG1 gene, in many but not all case-control and family studies. NRG1 is a pleiotropic growth factor, important in nervous system development and functioning; roles include the modulation of neuronal migration, synaptogenesis, gliogenesis, neuron-glia communication, myelination, and neurotransmission. Understanding the neurobiology of NRG1 and its involvement in schizophrenia is challenged by the complexity of the gene, which gives rise to multiple functionally distinct isoforms, including six "types" of NRG1 defined by 5' exon usage. Type IV and type I NRG1 may be particularly relevant to schizophrenia, with initial data showing altered expression of these isoforms in the disorder or in association with NRG1 risk alleles. We review the structure and functions of NRG1, consider the evidence for and against it being a schizophrenia susceptibility gene, and discuss mechanisms that might underlie the contribution of NRG1 to disease pathophysiology.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16442083     DOI: 10.1016/j.biopsych.2005.11.002

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  156 in total

1.  Disrupted activity in the hippocampal-accumbens circuit of type III neuregulin 1 mutant mice.

Authors:  Malcolm W Nason; Avishek Adhikari; Marjan Bozinoski; Joshua A Gordon; Lorna W Role
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

Review 2.  Genetics of psychosis of Alzheimer disease.

Authors:  Chintan Shah; Mary Ann A DeMichele-Sweet; Robert A Sweet
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2016-01-12       Impact factor: 3.568

Review 3.  Genetic neuropathology of schizophrenia: new approaches to an old question and new uses for postmortem human brains.

Authors:  Joel E Kleinman; Amanda J Law; Barbara K Lipska; Thomas M Hyde; Justin K Ellis; Paul J Harrison; Daniel R Weinberger
Journal:  Biol Psychiatry       Date:  2011-01-15       Impact factor: 13.382

Review 4.  Defects in Bioenergetic Coupling in Schizophrenia.

Authors:  Courtney R Sullivan; Sinead M O'Donovan; Robert E McCullumsmith; Amy Ramsey
Journal:  Biol Psychiatry       Date:  2017-10-24       Impact factor: 13.382

5.  A systematic meta-analysis of the association of Neuregulin 1 (NRG1), D-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia.

Authors:  Vinita Jagannath; Miriam Gerstenberg; Christoph U Correll; Susanne Walitza; Edna Grünblatt
Journal:  J Neural Transm (Vienna)       Date:  2017-09-01       Impact factor: 3.575

6.  Genetics and smoking.

Authors:  Anu Loukola; Jenni Hällfors; Tellervo Korhonen; Jaakko Kaprio
Journal:  Curr Addict Rep       Date:  2014-03-01

7.  The involvement of Type II Neuregulin-1 in rat visuospatial learning and memory.

Authors:  Adam R Taylor; Sara B Taylor; James I Koenig
Journal:  Neurosci Lett       Date:  2012-10-23       Impact factor: 3.046

8.  ErbB4-neuregulin signaling modulates synapse development and dendritic arborization through distinct mechanisms.

Authors:  Daria Krivosheya; Lucia Tapia; Joshua N Levinson; Kun Huang; Yunhee Kang; Rochelle Hines; Annie K Ting; Ann Marie Craig; Lin Mei; Shernaz X Bamji; Alaa El-Husseini
Journal:  J Biol Chem       Date:  2008-09-26       Impact factor: 5.157

9.  Individual differences in psychotic effects of ketamine are predicted by brain function measured under placebo.

Authors:  Garry D Honey; Philip R Corlett; Anthony R Absalom; Michael Lee; Edith Pomarol-Clotet; Graham K Murray; Peter J McKenna; Edward T Bullmore; David K Menon; Paul C Fletcher
Journal:  J Neurosci       Date:  2008-06-18       Impact factor: 6.167

Review 10.  Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects.

Authors:  Maarten van den Buuse
Journal:  Schizophr Bull       Date:  2009-11-09       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.